Haploidentical hematopoietic cell transplantation for mycosis fungoides/Sezary syndrome

2019 ◽  
Vol 61 (1) ◽  
pp. 231-233
Author(s):  
Margaret Kelsey Baron ◽  
James Dane Osborn ◽  
Randa Tao ◽  
Catherine J. Lee
Keyword(s):  
Cell Transplantation ◽  
Mycosis Fungoides ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Haploidentical Hematopoietic Cell Transplantation

scholarly journals Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome

2020 ◽  
Vol 13 (2) ◽  
pp. 1053-1058
Author(s):  
Madoka Kanda-Kato ◽  
Satoshi Yoshioka ◽  
Takayuki Ishikawa
Keyword(s):  
Cell Transplantation ◽  
Bacterial Infections ◽  
Hematopoietic Cell Transplantation ◽  
Cord Blood Transplantation ◽  
Infectious Complications ◽  
Hematopoietic Cell ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Blood Transplantation ◽  
Unrelated Cord Blood

Patients with advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS) have a poor prognosis. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment option; however, since most patients with MF/SS are elderly, they often have difficulty in finding HLA-matched donors. In recent years, HCT from HLA-haploidentical donors (haplo-HCT) using posttransplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis has been conducted for patients without HLA-matched donors. Infectious complications, particularly cutaneous bacterial infections, are common among patients with MF/SS. The lower incidence of severe infectious complications after haplo-HCT than after an unrelated cord blood transplantation could lead to lower transplant-related mortality. Here, we report on a patient with SS who was treated successfully with haplo-HCT with PTCy. The patient has remained in complete remission for more than 24 months.

scholarly journals HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis

2019 ◽  
Vol 3 (17) ◽  
pp. 2581-2585 ◽  
Author(s):  
Mohamad A. Meybodi ◽  
Wenhao Cao ◽  
Leo Luznik ◽  
Asad Bashey ◽  
Xu Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Meta Analysis ◽  
Hematopoietic Cell ◽  
Free Survival ◽  
Relative Contribution ◽  
Haploidentical Hematopoietic Cell Transplantation ◽  
Matched Sibling ◽  
Outcome Differences

Abstract HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ~50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.

Sign in / Sign up

Export Citation Format

Share Document